We report a case of congenital multisystem Langerhans cell histiocytosis with cutaneous and hematopoietic involvement. After the failure of first-line (vinblastine and prednisolone) and second-line (vincristine and cytarabine) therapies, treatment with cobimetinib, a mitogen-activated protein kinase (MEK) inhibitor, led to the remission of disease and a sustained response after 11 months of ongoing treatment. Protein kinase inhibitors targeting BRAF or MEK could represent a promising future therapeutic option, also in children with LCH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pde.15512 | DOI Listing |
Publication Analysis
Top Keywords
langerhans cell
8
cell histiocytosis
8
protein kinase
8
treatment congenital
4
congenital langerhans
4
histiocytosis cobimetinib
4
cobimetinib report
4
report case
4
case congenital
4
congenital multisystem
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!